On June 30, 2023, PERRIGO COMPANY ($NYSE:PRGO) reported its financial results for the second quarter of FY2023, with total revenue reaching USD 1193.1 million – an increase of 6.4% from the same period in the previous year. Net income also rose by 112.9%, totaling USD 8.4 million.
GoodWhale has examined the financials of PERRIGO COMPANY and found it to be classified as a ‘cow’. This type of company is known for its record of paying out consistent and sustainable dividends. Such a company may be of interest to investors looking for steady and reliable income streams. PERRIGO COMPANY is strong in dividend, medium in profitability and weak in asset and growth. However, when it comes to health, the company has a score of 7/10, indicating that it is able to weather any crisis without the risk of bankruptcy due to its cashflows and debt. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Perrigo Company. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Perrigo Company. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Perrigo Company. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Perrigo Company are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.
Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.
As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.
PERRIGO COMPANY saw a successful second quarter of FY2023, with total revenue increasing by 6.4% to USD 1193.1 million compared to the same period the previous year. Net income rose by a substantial 112.9% to USD 8.4 million, driving the stock price up. Investors can expect strong performance in the future, as PERRIGO COMPANY is able to generate significant returns and is well-positioned to benefit from market conditions. It has strong fundamentals, and its ability to capitalize on growth opportunities will likely lead to future success.